Annals of Oncology · 2023 · 13 citations · 27 references
Life SciencesImmunologyOncologyCancer ImmunologyImmunotherapyTumor ImmunologyCancer ImmunotherapyCheckpoint Inhibitor TherapyImmune Checkpoint InhibitorsImmune Checkpoint RegulationImmune CheckpointsImmunotherapy For Skin CancerChronic Lymphocytic Leukemia TherapyImmune Checkpoint Inhibitor TherapyImmune Checkpoint ReceptorsImmune Checkpoint ResistanceMelanoma ImmunotherapyResistance To Checkpoint InhibitorsResistance To Immune Checkpoint Inhibition
27
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. Eisenhauer, P. Therasse, Jan Bogaerts et al. · European Journal of Cancer · 2008 · 29.5K citations
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi, Steven O’Day, David F. McDermott et al. · New England Journal of Medicine · 2010 · 15.2K citations · Full text
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
James Larkin, Vanna Chiarion‐Sileni, René González et al. · New England Journal of Medicine · 2015 · 8.1K citations · Full text
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Jedd D. Wolchok, Vanna Chiarion‐Sileni, René González et al. · New England Journal of Medicine · 2017 · 5.4K citations · Full text
Pharmacy, Oncology, Pharmacotherapy +17
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Caroline Robert, L. Thomas, Igor Bondarenko et al. · New England Journal of Medicine · 2011 · 4.5K citations · Full text
Medicine, Oncology, Pharmacotherapy +12